Additionally, their expression was found to correlate with the clinical stage of pancreatic cancer (Table 1), so it is postulated that increased expression of SMURF1 and SMURF2 may have prognostic value in identifying patients with a poor outcome (Tables 1, 2; Figure 1). This evidence concerns the gene SMURF2 and familial pancreatic carcinoma.